Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) says the latest publication of phase III trial data provides important validation of its treatment, Grass MATA MPL.

The findings, shared in the journal Allergy, confirm the effectiveness of the company's short-course immunotherapy for grass pollen allergies.

The G306 study, completed in November 2023, showed a 20.3% improvement in allergy symptoms compared to a placebo during peak pollen season. This strong result supported the company's Marketing Authorisation Application to German regulators.

Grass MATA MPL is different from traditional allergy treatments. Instead of years of daily tablets or up to 100 jabs, it requires just six injections before allergy season. The latest data highlights how it works -- triggering a strong immune response through key antibodies that help protect against allergic reactions.

No other subcutaneous allergy treatment has shown better than 14% improvement in a phase III trial over the past decade. Grass MATA MPL's 20.3% improvement makes it stand out in the field. Patients also reported a 27.7% better quality of life, significantly higher than other grass allergy treatments.

With over 95% of trial participants completing the treatment, the company believes its short-course approach could be a game-changer for allergy sufferers.

"The publication of our G306 data in Allergy, one of the world's leading allergy journals, provides important validation of our innovative approach to allergy immunotherapy," said Allergy Therapeutics CEO Manuel Llobet.

"These results reinforce our confidence in Grass MATA MPL's potential to provide an important new treatment option for patients affected by seasonal grass allergy."